Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Breast and Gynecologic Cancers: Independent Conference Coverage of the 2021 ASCO Annual Meeting
  • CME

Joyce O'Shaughnessy, MD
Angeles Alvarez Secord, MD, MHSc
Released: August 12, 2021
Back Next

References

  1. Schmid P, Cortes J, Pusztai J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  2. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomized, double-blind, phase 3 trial. Lancet. 2020;396:1090-1100.
  3. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983-991.
  4. Adams S, Goldstein LJ, Sparano JA, et al. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015;4:e985930. Lancet Oncol. 2018;19:40-50. Cancers (Basel). 2021;13:746.
  5. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40-50.
  6. Grandal B, Mangiardi-Veltin M, Laas E, et al. PD-L1 expression after neoadjuvant chemotherapy in triple-negative breast cancers is associated with aggressive residual disease, suggesting a potential for immunotherapy. Cancers (Basel). 2021;13:746.
  7. Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30:1279-1288.
  8. Loibl S, Schneeweiss A, Huober JB, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 506.
  9. Nitz UA, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. Ann Oncol. 2017;28:2768-2772.
  10. Harbeck N, Gluz O, Christgen M, et al. De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 503.
  11. ClinicalTrials.gov. CompassHER2-pCR: decreasing chemotherapy for breast cancer patients after pre-surgery chemo and targeted therapy. clinicaltrials.gov/ct2/show/NCT04266249. Accessed August 3, 2021.
  12. Tutt A, Garber JE, Kaufman B, et al. OlympiA: a phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract LBA1.
  13. Tutt A, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405.
  14. Olaparib [prescribing information]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2021.
  15. ClinicalTrials.gov. Study of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant chemotherapy & adjuvant endocrine therapy in the treatment of early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer (MK-3475-756/KEYNOTE-756). clinicaltrials.gov/ct2/show/NCT03725059. Accessed August 3, 2021.
  16. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998.
  17. Martin M, Hegg R, Kim S-B, et al. Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 517.
  18. O’Shaughnessy JA, Johnston S, Harbeck N, et al. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer. Presented at: 2020 San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS1-01.
  19. Abemaciclib [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2020.
  20. Ribociclib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.
  21. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465-2472.
  22. Sledge Jr GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875-2884.
  23. Sledge Jr GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116-124.
  24. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209-219.
  25. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926-1936.
  26. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514-524.
  27. Slamon DJ, Neven P, Chia SKL, et al. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 1001.
  28. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32:1015-1024.
  29. Cristofanilli M, Rugo HS, Im S-A, et al. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 1000.
  30. Yardley DA, Nusch A, Yap YS, et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Presented at: 2020 American Society of Clinical Oncology Virtual Annual Meeting; May 29-31, 2020. Abstract 1054.
  31. Palbociclib [prescribing information]. Groton, CT: Pfizer Incorporated; 2019.
  32. Llombart-Cussac A, Pérez-García JM, Bellet M, et al. PARSIFAL: a randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer. Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020. Abstract 1007.
  33. Lam SY, Liu WS, Lee CS. A review of CDK4/6 inhibitors. US Pharm. 2020;45(Specialty&Oncology suppl):3-8.
  34. Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22:212-222.
  35. Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the Penelope-B trial. J Clin Oncol. 2021;39:1518-1530.
  36. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638-3646.
  37. Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.
  38. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.
  39. Sacituzumab govitecan [prescribing information]. Morris Plains, NJ: Immunomedics, Inc.; 2021.
  40. US Food and Drug Administration. FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer. Accessed August 3, 2021.
  41. Kalinsky K, Oliveira M, Traina TA, et al. Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 1011.
  42. O’Shaughnessy J, Punie K, Oliveira M, et al. Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 1077.
  43. Carey LA, Loirat D, Punie K, et al. Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 1080.
  44. Zola P, Ciccone G, Piovano E, et al. Intensive versus minimalist follow-up in patients treated for endometrial cancer: a multicentric randomized controlled trial (the TOTEM study—NCT00916708). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 5506.
  45. Society of Gynecologic Oncology. Choosing Wisely guidelines. choosingwisely.org/societies/society-of-gynecologic-oncology. Accessed August 3, 2021.
  46. Madariaga A, Garg S, Tchrakian N, et al. Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 5574.
  47. Tanyi JL, Chon HS, Morgan MA, et al. Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 5503.
  48. González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391.
  49. Liu JF, Gaillard S, Hendrickson AE, et al. An open-label phase 2 study of dostarlimab, bevacizumab, and niraparib combination in patients with platinum-resistant ovarian cancer. Presented at: 2021 Society of Gynecologic Oncology; March 19-25, 2021. Abstract 23.
  50. Wang H, Shu Jin, Zou D, et al. Preliminary results of niraparib and brivanib dual therapy evaluation in recurrent metastatic and persistent cervical cancer (CQGOGO101): an open-label, phase II clinical trial. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract e17506.
  51. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154-2164.
  52. González-Martín A, Matulonis UA, Korach J, et al. Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: results from three phase 3 niraparib trials. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 5518.
  53. Moore KN, Mirza MR, Matulonis UA. The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities. Gynecol Oncol. 2018;149:214-220.
  54. Westin SN, Coleman RL, Fellman BM, et al. EFFORT: EFFicacy Of adavosertib in parp ResisTance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 5505.
  55. Jacobs JM, Ream ME, Pensak N, et al. Patient experience with oral chemotherapy: adherence, symptoms, and quality of life. J Natl Compr Canc Netw. 2019;17:221-228.
  56. Marquina G, Manzano A, Casado A. Targeted agents in cervical cancer: beyond bevacizumab. Curr Oncol Rep. 2018;20:40.
  57. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
  58. Mileshkin LR, Moore KN, Barnes E, et al. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract LBA3.
  59. Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29:1678-1685.
  60. Roura E, Castellsagué X, Pawlita M, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int J Cancer. 2014;135:453-466.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings